Latest Biotech News

Stereotaxis received U.S. FDA clearance for its Magic magnetic interventional ablation catheter, marking the device maker’s first proprietary robotic ablation catheter authorized for use in the...

Pfizer and Cartography Biosciences announced a collaboration to identify tumor-selective antigens using Cartography’s ATLAS and SUMMIT discovery platforms. The multi-option deal includes about $65...

Federal health officials announced an abrupt reduction in the number of vaccines the Centers for Disease Control and Prevention will universally recommend for children, cutting the routine list...

Eli Lilly expanded its metabolic pipeline by signing a multiyear discovery and exclusive worldwide license with Nimbus Therapeutics focused on an oral obesity program, with total value potential...

Arrowhead Pharmaceuticals released early clinical data showing its RNAi candidates produced meaningful fat loss when combined with Lilly’s tirzepatide (Zepbound), including disproportionate...

Amgen agreed to acquire U.K.-based Dark Blue Therapeutics in a deal worth up to $840 million, adding a preclinical small molecule degrader aimed at MLLT1/3 to its oncology pipeline. Amgen said the...

Sanofi struck a definitive agreement to acquire Dynavax Technologies for approximately $2.2 billion in cash, adding Dynavax’s adult hepatitis B vaccine (HEPLISAV‑B) and a Phase I/II shingles...

Insilico Medicine signed a multiyear R&D collaboration with Servier valued at up to $888 million to discover and develop oncology therapeutics using Insilico’s AI discovery platform. The agreement...

Alumis reported positive top-line results from two Phase 3 trials (Onward1 and Onward2) of envudeucitinib, a selective oral TYK2 inhibitor, meeting co‑primary endpoints for skin clearance in...

Bright Minds Biosciences announced positive Phase 2 seizure-reduction data for its selective serotonin receptor agonist candidate, reporting statistically significant reductions across two seizure...

Moderna submitted regulatory applications in the U.S., Europe, Canada and Australia seeking approval for its mRNA seasonal flu vaccine candidate mRNA‑1010, targeted initially to people aged 50 and...

A U.S. Court of Appeals affirmed a permanent injunction that prevents the National Institutes of Health from imposing a 15% cap on indirect cost reimbursements for all grant recipients. The First...

Eli Lilly renewed a multi-year R&D partnership with Nimbus Therapeutics to pursue an oral small-molecule obesity program, agreeing to roughly $55 million in upfront and near-term payments and up...

Arrowhead Pharmaceuticals reported early-phase signals from its RNAi obesity programs, including ARO‑INHBE dosed in combination with Lilly’s tirzepatide (Zepbound). Interim results indicated...

Alumis reported topline Phase 3 results for envudeucitinib, a selective oral TYK2 inhibitor, showing statistically significant skin‑clearance outcomes in two pivotal ONWARD trials for...

Amgen agreed to acquire Dark Blue Therapeutics for up to $840 million to add a preclinical small-molecule degrader targeting MLLT1/3 and related programs aimed at acute myeloid leukemia (AML)....

Sanofi expanded its collaboration with AI-driven biologics developer Earendil Labs to discover and develop bispecific antibodies for autoimmune and inflammatory diseases. The agreement carries...

Federal health officials revised the U.S. childhood immunization schedule, reducing routine universal recommendations from 17 diseases to 11. The change—announced under HHS direction—moves...

The U.S. Court of Appeals for the First Circuit upheld a permanent injunction preventing the National Institutes of Health from imposing a 15% across‑the‑board cap on indirect (overhead) costs for...

Bright Minds Biosciences announced positive Phase 2 results for its selective serotonin receptor agonist BMB‑101, showing clinically meaningful seizure reductions across two seizure types. The...